FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385667044> ?p ?o ?g. }

• W4385667044 endingPage "e5903029" @default.
• W4385667044 startingPage "e5903029" @default.
• W4385667044 abstract "Background: Patients (pts) with lower risk myelodysplastic syndromes (LR-MDS) and anemia experience severe fatigue that negatively impacts overall functioning and daily life. Fatigue can also be commonly reported with treatments for LR-MDS, the goals of which are to minimize transfusions and improve pt-reported outcomes (PRO). In the IMerge Phase 3 (Ph3) study (NCT02598661), imetelstat, a first-in-class telomerase inhibitor, demonstrated statistically significant and meaningfully improved 8- and 24-wk transfusion independence (TI) rates, durable TI, and increased hemoglobin levels compared with placebo in heavily red blood cell (RBC) transfusion-dependent (TD) non-del(5q) LR-MDS pts who were ineligible/relapsed/refractory to ESA and naive to lenalidomide/hypomethylating agents. We also evaluated pt reported fatigue (rate of deterioration/improvement) during treatment with imetelstat or placebo. Aims: Explore impact of imetelstat or placebo on pt-reported fatigue in IMerge Ph3. Methods: To measure pt-reported fatigue, an exploratory analysis, data were collected using the validated Functional Assessment of Chronic Illness Therapy (FACIT) Scale and analyzed in all randomized pts with available fatigue data at baseline (PRO population). The FACIT is a 13-item questionnaire measuring fatigue during daily activity. Proportion of sustained meaningful deterioration/improvement was defined as percentage of pts with ≥3-point decrease/increase on the FACIT Fatigue Scale (0–52) for ≥2 consecutive treatment cycles. Time-to-deterioration/improvement was estimated by Kaplan-Meier analysis. Sensitivity analyses were performed in the intent-to-treat population and with alternate definitions of meaningful deterioration. Results: The PRO population included 118 pts on imetelstat and 57 pts on placebo. Completion rates for all PRO items were >80% at most visits throughout the study in both groups. At baseline, mean age was 71 years (range, 39–87), Eastern Cooperative Oncology Group performance status was 0 (36.0%), 1 (60.6%), or 2 (3.4%), and 62.3% of pts were male. The proportion of pts who experienced any episode of sustained, meaningful deterioration in fatigue during this study was 43.2% in the imetelstat group and 45.6% in the placebo group. Results of sensitivity analyses were similar to the main analysis. Overall, 50.0% of pts on imetelstat reported sustained meaningful improvement in fatigue vs 40.4% of pts on placebo. A shorter median time to reported first sustained meaningful improvement in fatigue occurred with imetelstat vs placebo; 28.3 vs 65.0 wks, HR=1.34 (95% CI, 0.82–2.20). After 12 wks, more pts on imetelstat reported improvement in the FACIT Fatigue Scale than on placebo, Figure a. In imetelstat-treated pts, a significantly higher proportion of responders had sustained meaningful improvement in fatigue scores vs non-responders, consistent across 8- and 24-wk TI and HI-E per IWG 2006; an association was not observed in placebo-treated pts, Figure b. Summary/Conclusion: In this heavily TD population, both imetelstat- and placebo-treated pts reported similar rates of deterioration in fatigue, suggesting imetelstat did not worsen the rate of deterioration, which has been reported with other available treatments. After 12 wks, greater improvement in fatigue was reported with imetelstat compared to placebo; pts on imetelstat were more likely to have sustained meaningful improvement in fatigue and quicker to experience it. A significant association between TI and HI-E responses and sustained meaningful improvement in fatigue support the clinical benefit of imetelstat treatment. Mikkael A. Sekeres and Valeria Santini contributed equally. Amer M. Zeidan and Uwe Platzbecker contributed equally.Keywords: Myelodysplastic syndrome, Fatigue, Therapy, Telomerase activity" @default.
• W4385667044 created "2023-08-09" @default.
• W4385667044 creator A5010075752 @default.
• W4385667044 creator A5014371922 @default.
• W4385667044 creator A5014838075 @default.
• W4385667044 creator A5020211212 @default.
• W4385667044 creator A5023778427 @default.
• W4385667044 creator A5030798486 @default.
• W4385667044 creator A5043558209 @default.
• W4385667044 creator A5044809473 @default.
• W4385667044 creator A5045122197 @default.
• W4385667044 creator A5048054881 @default.
• W4385667044 creator A5048469868 @default.
• W4385667044 creator A5048763642 @default.
• W4385667044 creator A5049400849 @default.
• W4385667044 creator A5054251988 @default.
• W4385667044 creator A5055740968 @default.
• W4385667044 creator A5062094994 @default.
• W4385667044 creator A5062937325 @default.
• W4385667044 creator A5067521829 @default.
• W4385667044 creator A5075211980 @default.
• W4385667044 creator A5076437843 @default.
• W4385667044 creator A5077959613 @default.
• W4385667044 creator A5078437962 @default.
• W4385667044 creator A5079124367 @default.
• W4385667044 creator A5084726862 @default.
• W4385667044 creator A5090985347 @default.
• W4385667044 creator A5091318797 @default.
• W4385667044 date "2023-08-01" @default.
• W4385667044 modified "2023-10-17" @default.
• W4385667044 title "P732: ANALYSIS OF PATIENT-REPORTED FATIGUE IN IMERGE PH3 TRIAL OF IMETELSTAT VS PLACEBO IN HEAVILY TRANSFUSED NON-DEL(5Q) LOWER-RISK MYELODYSPLASTIC SYNDROMES R/R TO ERYTHROPOIESIS STIMULATING AGENTS" @default.
• W4385667044 doi "https://doi.org/10.1097/01.hs9.0000969832.59030.29" @default.
• W4385667044 hasPublicationYear "2023" @default.
• W4385667044 type Work @default.
• W4385667044 citedByCount "0" @default.
• W4385667044 crossrefType "journal-article" @default.
• W4385667044 hasAuthorship W4385667044A5010075752 @default.
• W4385667044 hasAuthorship W4385667044A5014371922 @default.
• W4385667044 hasAuthorship W4385667044A5014838075 @default.
• W4385667044 hasAuthorship W4385667044A5020211212 @default.
• W4385667044 hasAuthorship W4385667044A5023778427 @default.
• W4385667044 hasAuthorship W4385667044A5030798486 @default.
• W4385667044 hasAuthorship W4385667044A5043558209 @default.
• W4385667044 hasAuthorship W4385667044A5044809473 @default.
• W4385667044 hasAuthorship W4385667044A5045122197 @default.
• W4385667044 hasAuthorship W4385667044A5048054881 @default.
• W4385667044 hasAuthorship W4385667044A5048469868 @default.
• W4385667044 hasAuthorship W4385667044A5048763642 @default.
• W4385667044 hasAuthorship W4385667044A5049400849 @default.
• W4385667044 hasAuthorship W4385667044A5054251988 @default.
• W4385667044 hasAuthorship W4385667044A5055740968 @default.
• W4385667044 hasAuthorship W4385667044A5062094994 @default.
• W4385667044 hasAuthorship W4385667044A5062937325 @default.
• W4385667044 hasAuthorship W4385667044A5067521829 @default.
• W4385667044 hasAuthorship W4385667044A5075211980 @default.
• W4385667044 hasAuthorship W4385667044A5076437843 @default.
• W4385667044 hasAuthorship W4385667044A5077959613 @default.
• W4385667044 hasAuthorship W4385667044A5078437962 @default.
• W4385667044 hasAuthorship W4385667044A5079124367 @default.
• W4385667044 hasAuthorship W4385667044A5084726862 @default.
• W4385667044 hasAuthorship W4385667044A5090985347 @default.
• W4385667044 hasAuthorship W4385667044A5091318797 @default.
• W4385667044 hasBestOaLocation W43856670441 @default.
• W4385667044 hasConcept C126322002 @default.
• W4385667044 hasConcept C142724271 @default.
• W4385667044 hasConcept C1862650 @default.
• W4385667044 hasConcept C204787440 @default.
• W4385667044 hasConcept C27081682 @default.
• W4385667044 hasConcept C2778248108 @default.
• W4385667044 hasConcept C2780007613 @default.
• W4385667044 hasConcept C2780817109 @default.
• W4385667044 hasConcept C2908647359 @default.
• W4385667044 hasConcept C71924100 @default.
• W4385667044 hasConcept C99454951 @default.
• W4385667044 hasConceptScore W4385667044C126322002 @default.
• W4385667044 hasConceptScore W4385667044C142724271 @default.
• W4385667044 hasConceptScore W4385667044C1862650 @default.
• W4385667044 hasConceptScore W4385667044C204787440 @default.
• W4385667044 hasConceptScore W4385667044C27081682 @default.
• W4385667044 hasConceptScore W4385667044C2778248108 @default.
• W4385667044 hasConceptScore W4385667044C2780007613 @default.
• W4385667044 hasConceptScore W4385667044C2780817109 @default.
• W4385667044 hasConceptScore W4385667044C2908647359 @default.
• W4385667044 hasConceptScore W4385667044C71924100 @default.
• W4385667044 hasConceptScore W4385667044C99454951 @default.
• W4385667044 hasIssue "S3" @default.
• W4385667044 hasLocation W43856670441 @default.
• W4385667044 hasLocation W43856670442 @default.
• W4385667044 hasOpenAccess W4385667044 @default.
• W4385667044 hasPrimaryLocation W43856670441 @default.
• W4385667044 hasRelatedWork W2033556677 @default.
• W4385667044 hasRelatedWork W2034349976 @default.
• W4385667044 hasRelatedWork W2091771435 @default.
• W4385667044 hasRelatedWork W2094293739 @default.
• W4385667044 hasRelatedWork W2118552577 @default.
• W4385667044 hasRelatedWork W2433294562 @default.
• W4385667044 hasRelatedWork W2588524359 @default.
• W4385667044 hasRelatedWork W2801725202 @default.

• next